Cissus Extract

SRBio Cissus Quadrangularis Extract: Dual-Action Formula for Metabolic Health & Joint Support — Backed by 12.8% Fat Loss in 8 Weeks*

Section 1: Scientific Foundation & Dual Benefits

1.1 Weight Management: Clinically Validated Fat Reduction

• Core Mechanism: Inhibits DPP-4 enzyme activity (+94% vs. placebo) and elevates GLP-1 levels (+68%), enhancing satiety, delaying gastric emptying, and promoting glucose homeostasis.

• Human Clinical Results:

  • 12.8% body fat reduction in 8 weeks (DEXA scan; p<0.01) with 300 mg/day dosing.

  • Significant improvements in metabolic markers:

    • ↓ 8.9% waist circumference

    • ↓ 15.3% triglycerides

    • ↓ 12.4% fasting glucose.

  • Superior to synthetic DPP-4 inhibitors (e.g., sitagliptin): No pancreatitis or Stevens-Johnson syndrome risk.

1.2 Bone & Joint Health: Synergistic Action

• Osteogenic Activation: Stimulates osteoblast proliferation (+37% vs. control) and increases bone thickness in osteoporosis models.

• Anti-Inflammatory Effects: Dual inhibition of COX/LOX pathways, reducing edema by 52% in arthritis trials.

Section 2: SRBio’s Advanced Manufacturing Advantages

2.1 Precision Extraction & Standardization

• Active-Driven Formulations: Options for 5%, 10%, or 40% Ketosterones (key biomarkers for metabolic/joint efficacy). Custom ratios available.

• Solvent-Free Purification: Removes heavy metals (≤0.1 ppm), pesticides (ND), and microbial contaminants (TBC <100 CFU/g)1.

2.2 Clinically Backed & Research-Optimized

• Mechanism Validation: Collaboration with University of Yaounde to confirm GLP-1/DPP-4 modulation and cartilage protection.

• Dose-Specific Formats:

  • Weight Management: 300 mg capsules (aligned with CQR-300® trial protocols).

  • Joint Support: 1,200 mg formulations for osteoarthritis.

2.3 End-to-End Quality & Compliance

• cGMP/ISO 9001 Facilities: 7,000 m² production base with HPLC-validated batch testing.

• Full Traceability: Sustainably wild-harvested in Africa/Asia; vertical integration from raw material to extract.

2.4 Technical Partnership & Scalability

• Custom Solutions: Water-soluble powders, enteric-coated capsules, and private-label blends.

• Global Logistics: MOQ 1KG; capacity 300,000 kg/month with temperature-controlled shipping.

Section 3: Product Specifications & Applications

Applications:

• Weight Management Supplements: 300 mg/day capsules/powders.

• Joint Health Formulas: 1,200 mg tablets with glucosamine synergy.

• Functional Foods: Bars, shakes, and beverages (thermal stability: ≤120°C).

Section 4: Safety & Regulatory Assurance

• Toxicology Profile: LD50 >5,000 mg/kg (acute oral); no genotoxicity in AMES test1.

• Global Compliance: Meets FDA GRAS, EU Novel Food, and APAC regulatory standards.

• Full Documentation: Batch-specific CoA, stability data (24 months), and clinical dossiers.

Video & Articles

Factory Tour

Shipping & Packing Information

Would You Like To Learn More?